Alvotech acquires Xbrane’s R&D operations and the biosimilar candidate XB003. Xbrane retains some pre-clinical development programs, that it intends to commercialize, and will continue operating as a ...

Thursday announced the acquisition of Xbrane Biopharma AB’s R&D operations and a biosimilar candidate, establishing a footprint in the Swedish life science sector. The acquisition’s purchase price ...

Alvotech acquires Xbrane's R&D operations and biosimilar candidate for SEK 275 million, enhancing development capabilities and expanding into Sweden.

Icelandic biotechnology company Alvotech intends to explore the possibility of a Stockholm listing as it announced the acquisition of a Swedish research and development operation and drug candidate.

“The FDA's filing acceptance of Dr. Reddy's proposed denosumab biosimilar marks an important milestone in bringing this biosimilar medication to more patients throughout the U.S.,” said Milan ...

Dr. Reddy’s Laboratories RDY and partner, Alvotech ALVO, announced the FDA’s acceptance of a regulatory filing, seeking the ...

This marks the second biosimilar released in the U.S. by the strategic partnership between Teva Pharmaceuticals and Alvotech, which is committed to providing more affordable treatment options.

Alvotech has developed a biosimilar of Humira called AVT02, the first-filed biosimilar drug equal in strength to Humira’s latest formulation, which AbbVie markets as a high-concentration, pain ...

REYKJAVIK, Iceland and PARSIPPANY, N.J., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines ...

REYKJAVIK, Iceland, March 07, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the ...

Teva and Alvotech's Selarsdi, like Stelara, is approved for the treatment of moderate to severe plaque psoriasis, active psoriatic arthritis, and moderately to severely active Crohn's disease and ...

In October 2024, the FDA approved the biosimilar SELARSDI™ (ustekinumab-aekn), manufactured by Teva Pharmaceuticals in partnership with Alvotech, for various conditions similar to those treated ...